1030 related articles for article (PubMed ID: 19216016)
21. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
22. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
van Essen GG; Apperloo AJ; Rensma PL; Stegeman CA; Sluiter WJ; de Zeeuw D; de Jong PE
Kidney Int Suppl; 1997 Dec; 63():S58-62. PubMed ID: 9407423
[TBL] [Abstract][Full Text] [Related]
23. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease.
Jones C; Roderick P; Harris S; Rogerson M
Nephrol Dial Transplant; 2006 Aug; 21(8):2133-43. PubMed ID: 16644779
[TBL] [Abstract][Full Text] [Related]
24. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P; Perna A; Mosconi L; Matalone M; Pisoni R; Gaspari F; Remuzzi G
Kidney Int Suppl; 1997 Dec; 63():S54-7. PubMed ID: 9407422
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials.
Hermsen ED; Maiefski M; Florescu MC; Qiu F; Rupp ME
Pharmacotherapy; 2009 Jun; 29(6):649-55. PubMed ID: 19476418
[TBL] [Abstract][Full Text] [Related]
26. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease.
Tonelli M; Isles C; Craven T; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; West M; Packard C; Curhan GC
Circulation; 2005 Jul; 112(2):171-8. PubMed ID: 15998677
[TBL] [Abstract][Full Text] [Related]
27. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Renke M; Tylicki L; Rutkowski P; Knap N; Zietkiewicz M; Neuwelt A; Aleksandrowicz E; Łysiak-Szydłowska W; Woźniak M; Rutkowski B
Acta Biochim Pol; 2010; 57(1):119-23. PubMed ID: 20309434
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
Sinsakul M; Sika M; Rodby R; Middleton J; Shyr Y; Chen H; Han E; Lehrich R; Clyne S; Schulman G; Harris R; Lewis J
Am J Kidney Dis; 2007 Dec; 50(6):946-51. PubMed ID: 18037095
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
30. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
31. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.
Levin A; Djurdjev O; Beaulieu M; Er L
Am J Kidney Dis; 2008 Oct; 52(4):661-71. PubMed ID: 18805347
[TBL] [Abstract][Full Text] [Related]
32. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment.
Penne EL; Neumann J; Klein IH; Oey PL; Bots ML; Blankestijn PJ
J Nephrol; 2009; 22(2):208-15. PubMed ID: 19384838
[TBL] [Abstract][Full Text] [Related]
33. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.
Ando M; Ohashi K; Akiyama H; Sakamaki H; Morito T; Tsuchiya K; Nitta K
Nephrol Dial Transplant; 2010 Jan; 25(1):278-82. PubMed ID: 19762604
[TBL] [Abstract][Full Text] [Related]
34. Restricted protein diet is associated with decrease in proteinuria: consequences on the progression of renal failure.
Chauveau P; Combe C; Rigalleau V; Vendrely B; Aparicio M
J Ren Nutr; 2007 Jul; 17(4):250-7. PubMed ID: 17586423
[TBL] [Abstract][Full Text] [Related]
35. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
[TBL] [Abstract][Full Text] [Related]
36. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
[TBL] [Abstract][Full Text] [Related]
37. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
38. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC
Am J Kidney Dis; 2004 Nov; 44(5):832-9. PubMed ID: 15492949
[TBL] [Abstract][Full Text] [Related]
39. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
Onuigbo MA; Onuigbo NT
QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
[TBL] [Abstract][Full Text] [Related]
40. Stabilization of glomerular filtration rate in advanced chronic kidney disease: a two-year follow-up of a cohort of chronic kidney disease patients stages 4 and 5.
Serrano A; Huang J; Ghossein C; Nishi L; Gangavathi A; Madhan V; Ramadugu P; Ahya SN; Paparello J; Khosla N; Schlueter W; Batlle D
Adv Chronic Kidney Dis; 2007 Jan; 14(1):105-12. PubMed ID: 17200050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
